BYDUREON Pen Launch – Practical Considerations for Patients With Type 2 Diabetes
Speakers: A/Prof Jonathan Shaw and A/Prof Jane Overland
Advances in medicine over the last decade have allowed us to rethink the way we treat people with Type 2 Diabetes and provide individualised solutions to help them achieve goals. AstraZeneca is excited to share with you updates in its portfolio of medicines with the launch of the BYDUREON Pen (exenatide QW) in Australia.
This breakfast session will focus on BYDUREON Pen and the practical considerations when starting patients on the medicine. BYDUREON Pen is the first once weekly treatment available in Australia and represents a shift in the way we treat patients with type 2 diabetes. This meeting will cover the clinical trial programme for BYDUREON focusing on efficacy and safety compared with other glucose lowering medicines.
Associate Professor Jonathan Shaw and Associate Professor Jane Overland will be presenting updates on BYDUREON Pen during the breakfast session on Thursday.
Visit the ADS ADEA Conference website for more detail- http://ads-adea.org.au/industry-trade-breakfast-symposia/